比较立即治愈性治疗与保守治疗在≥75岁非转移性高危前列腺癌男性中的随机对照试验方案(SPCG 19/GRand-P)
SPCG 19/GRand-P是一项在北欧四国开展的多中心III期随机对照试验,计划纳入980例≥75岁非转移性高危前列腺癌男性,经G8和Mini-COG筛查后按1:1随机接受立即治愈性治疗或保守治疗,主要终点为总生存和健康相关生活质量,随访10年。
要点
- ≥75岁非转移性高危前列腺癌男性随机接受立即治愈性治疗或保守治疗。
- 主要终点为总生存和健康相关生活质量,随访10年。
- 计划纳入980例,经G8和Mini-COG筛查后按1:1随机。
核心结论
- 目前尚不清楚与保守治疗相比,治愈性治疗能否延长该年龄组患者的生存并改善健康相关生活质量。
研究设计与样本
- 斯堪的纳维亚前列腺癌组(SPCG)19/挪威Get-Randomized研究组-前列腺(GRand-P)是一项随机、双臂、对照、多中心、III期试验,在挪威、丹麦、芬兰和瑞典的研究中心开展。
- 计划纳入980例≥75岁非转移性高危前列腺癌男性,先用Geriatric 8(G8)健康状况筛查工具和Mini-COG©简易认知测试筛查。
- 被G8判定为「fit」或「frail」的参与者按1:1随机接受立即治愈性治疗(放疗或前列腺切除术)或保守治疗(内分泌治疗或观察)。
- 无法或不愿参与随机化的参与者纳入单独的观察组,随机患者随访10年。
关键数值与推荐
- 主要终点为总生存和健康相关生活质量(疾病负担量表,欧洲癌症研究与治疗组织[EORTC]老年癌症患者量表)。
- 次要终点包括前列腺癌特异性生存、无转移生存、角色功能量表(EORTC生活质量问卷30项核心量表)、泌尿刺激/梗阻量表(26项扩展前列腺癌指数综合[EPIC-26])、肠道量表(EPIC-26)、无干预生存、前列腺癌发病率、二线和三线全身治疗的使用、平均质量调整生命年(QALYs)和平均总医疗费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs life and improves health-related quality of life (HRQoL) in this age group compared to conservative therapy, which has evolved considerably during the last decade. STUDY DESIGN: The Scandinavian Prostate Cancer Group (SPCG) 19/Norwegian Get-Randomized Research Group-Prostate (GRand-P) is a randomised, two-armed, controlled, multicentre, phase III trial carried out at study centres in Norway, Denmark, Finland, and Sweden. ENDPOINTS: The primary endpoints are overall survival and HRQoL (burden of disease scale, European Organisation for the Research and Treatment of Cancer [EORTC] Elderly Cancer patients). Secondary endpoints are PCa-specific survival, metastasis-free survival, role-functioning scale (EORTC quality of life questionnaire 30-item core), urinary irritative/obstructive scale (26-item Expanded Prostate Cancer Index Composite [EPIC-26]), bowel scale (EPIC-26), intervention-free survival, PCa morbidity, use of secondary and tertiary systemic therapies, mean quality-adjusted life-years (QALYs), and mean total healthcare costs. PATIENTS AND METHODS: A total of 980 men (aged ≥75 years) with non-metastatic, high-risk PCa will initially be screened with Geriatric 8 (G8) health status screening tool and Mini-COG© brief cognitive test. Participants identified by G8 as 'fit' or 'frail' will be randomised (ratio 1:1) to either immediate curative therapy (radiotherapy or prostatectomy) or conservative therapy (endocrine therapy or observation). Participants who are unable or unwilling to participate in randomisation will be enrolled in a separate observation group. Randomised patients will be followed for 10 years. TRIAL REGISTRATION: Ethics approval has been granted in Norway (457593), Denmark (H-22051998), Finland (R23043) and Sweden (Dnr 2023-05296-01). The trial is registered on Clinicaltrials.org (NCT05448547).
引用
- Löffeler S, Bertilsson H, Müller C, et al. Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P). BJU Int. 2024. PMID: 38469686. doi:10.1111/bju.16314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。